Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.

Authors :: Singh AM
Guevara-Patino JA
Wang X
Li R
Sonpavde G
Jain RK
Source :: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2023 Jul; Vol. 37 (4), pp. 505-520. Date of Electronic Publication: 2023 May 31.
Publication Year :: 2023
Abstract: Antibody-drug conjugates (ADCs) have transformed the treatment landscape in oncology and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs that have been especially successful in clinical practice are enfortumab vedotin and sacituzumab govitecan. These drugs are currently approved as monotherapy for later lines of treatment in locally advanced or metastatic UC and have had a significant impact for patients with limited treatment options. Combinational trials, as well as additional ADCs, are currently being investigated in the treatment of UC for subsequent lines of therapy as overall survival rates remain dismal.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)

Subjects :: Humans
Penicillins
Carcinoma, Transitional Cell drug therapy
Urinary Bladder Neoplasms drug therapy
Immunoconjugates therapeutic use

Language :: English
ISSN :: 1179-190X
Volume :: 37
Issue :: 4
Database :: MEDLINE
Journal :: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Publication Type :: Academic Journal
Accession number :: 37256534
Full Text :: https://doi.org/10.1007/s40259-023-00606-5